Qianjiang Yongan Pharmaceutical Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Qianjiang Yongan Pharmaceutical Co., Ltd. carries a market capitalization of 3.22B, placing it among publicly traded companies globally.
| Market Cap | 3.22B |
| Enterprise Value | N/A |
Share Statistics
Qianjiang Yongan Pharmaceutical Co., Ltd. currently has 294.68M shares outstanding.
| Shares Outstanding | 294.68M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Qianjiang Yongan Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 355.27. The price-to-sales ratio is 9.91, and the price-to-book ratio stands at 6.94.
| PE Ratio | 355.27 |
| PS Ratio | 9.91 |
| PB Ratio | 6.94 |
| P/TBV Ratio | 4.01 |
| P/FCF Ratio | 87.67 |
| P/OCF Ratio | N/A |
Financial Position
Qianjiang Yongan Pharmaceutical Co., Ltd. maintains a current ratio of 4.81, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.81 |
| Quick Ratio | 3.81 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -3.48 |
Financial Efficiency
| Return on Equity (ROE) | 1.94 |
| Return on Assets (ROA) | 0.95 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 2.27 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 7.18 |
Taxes
Over the trailing twelve months, Qianjiang Yongan Pharmaceutical Co., Ltd. has paid 2.40M in income taxes, reflecting an effective tax rate of 12.29.
| Income Tax | 2.40M |
| Effective Tax Rate | 12.29 |
Stock Price Statistics
Qianjiang Yongan Pharmaceutical Co., Ltd.'s stock has declined approximately -64.28105% over the past 52 weeks. The 50-day moving average sits at 12.06, while the 200-day moving average is 14.72.
| Beta (5Y) | N/A |
| 52-Week Price Change | -64.28105% |
| 50-Day Moving Average | 12.06 |
| 200-Day Moving Average | 14.72 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Qianjiang Yongan Pharmaceutical Co., Ltd. generated 780.38M in revenue and converted that into 21.78M in net income, yielding earnings per share of 0.06. EBITDA reached -3.08M, while operating income came in at -3.08M.
| Revenue | 780.38M |
| Gross Profit | 113.30M |
| Operating Income | -3.08M |
| Pretax Income | 19.55M |
| Net Income | 21.78M |
| EBITDA | -3.08M |
| EBIT | -3.08M |
| Earnings Per Share (EPS) | 0.06 |
Balance Sheet
Total book value stands at 1.12B, with working capital of 932.40M providing operational flexibility.
| Cash & Cash Equivalents | 931.01M |
| Total Debt | N/A |
| Net Debt | -233.91M |
| Equity (Book Value) | 1.12B |
| Book Value Per Share | 3.86 |
| Working Capital | 932.40M |
Cash Flow
After subtracting -88.24M in capital expenditures, free cash flow totaled -88.24M - equivalent to -0.31 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -88.24M |
| Free Cash Flow | -88.24M |
| FCF Per Share | -0.31 |
Margins
Qianjiang Yongan Pharmaceutical Co., Ltd. operates with a gross margin of 14.52, reflecting its pricing power and cost economics. The operating margin of -0.40 and net profit margin of 2.79 provide insight into operational efficiency.
| Gross Margin | 14.52 |
| Operating Margin | -0.40 |
| Pretax Margin | 2.51 |
| Profit Margin | 2.79 |
| EBITDA Margin | -0.40 |
Dividends & Yields
The company's payout ratio of 166.90 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.07 |
| Dividend Yield | N/A |
| Payout Ratio | 166.90 |
| Shareholder Yield | 0.61 |
| FCF Yield | 1.14 |
Stock Splits
Qianjiang Yongan Pharmaceutical Co., Ltd.'s most recent stock split took place on May 15, 2018 with a 2:3 split ratio.
| Last Split Date | 5/15/2018 |
| Split Ratio | 2:3 |
Scores
Qianjiang Yongan Pharmaceutical Co., Ltd. posts an Altman Z-Score of 19.22, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 19.22 |